Developer docs
API playgroundTry for free, no card

Search company profiles

Nesa World

Full company profile

uuid002naqd

Namestring
Nesa World
Legal namestring
NGS Health and Mind S.L
Websiteurl
nesa.world
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Nesa World (legally NGS Health and Mind S.L.) is a privately held Spanish medical technology company headquartered in San Sebastián (Donostia), Spain, that develops and distributes NESA XSIGNAL®, a Class IIa medical device for non-invasive autonomic neuromodulation. The device applies subsensory microcurrents (below 1 mA) through 24 surface electrodes placed on the wrists and ankles, delivering up to 19,000 bioelectrical impulses per minute at frequencies between 1 and 14 Hz. Its mechanism acts through three complementary pathways: classical afferent neurotransmission via peripheral nerves to the brainstem, bioelectrical communication through the piezoelectric fascial network, and neuroimmune modulation via the vagal pathway, with the goal of restoring sympathetic-parasympathetic balance in patients with chronic pain, sleep disturbances, fatigue, overactive bladder, stress, and related conditions.

The company sells the device through three tiers (Esencial, Profesional, Premium) to independent clinics, hospitals, and research institutions across more than 47 countries, with over 1,000 clinics and 50+ hospitals in its installed base and 4M+ cumulative patient sessions performed. Revenue is generated primarily through one-time hardware sales (with flexible acquisition options including outright purchase, payment plans, and rental for select home use), supplemented by recurring consumables (personal patient kits assigned per patient for hygiene and traceability), training and education services via the NESA Academic campus, and scientific dossier and research support services. Distribution combines a direct authorized clinic network, regional distributors, and academic/hospital research partnerships, supported by a public clinic locator and a multi-language marketing presence targeting healthcare professionals across rehabilitation, urogynecology, sports medicine, mental health, neurology, dentistry, internal medicine, and aesthetic medicine.

Nesa World's competitive positioning rests on more than three decades of technology evolution from a 192-electrode Japanese prototype, a portfolio of 16+ peer-reviewed clinical studies in indexed journals, a dedicated Electrophysiology Laboratory at ULPGC, and 15+ institutional research collaborations. The company is privately held with no disclosed external funding rounds, and operates with a headcount of 11–50 employees.

Short descriptiontext

Nesa World is a privately held Spanish medical technology company that develops and distributes NESA XSIGNAL®, a Class IIa non-invasive autonomic neuromodulation device sold to independent clinics, hospitals, and research institutions across 47+ countries for chronic pain, sleep, fatigue, and urological indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDonostia-san Sebastián, Spain
HQ citystring
Donostia-san Sebastián
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuromodulation medical devices, non-invasive therapy, autonomic nervous system, electrode medical device, clinical treatment systems
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Neuromodulation Medical Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Medical Device Sales – NESA XSIGNAL®
TypeHardware Sales
Description

Nesa World sells NESA XSIGNAL® medical devices (Class IIa) to healthcare professionals and clinics through a tiered offering model (Esencial, Profesional, Premium). The device is offered with flexible acquisition options including outright purchase, payment plans, and device rental for home treatment in select cases. Many clinics amortize the investment within the first months by bundling the device into session packages. Each tier includes varying levels of onboarding, training, clinical materials, and support. The revenue is predominantly a one-time capital expense for the device, supplemented by ongoing consumables (personal patient kits) and potentially premium support contracts.

nesa.world
2Session Packages and Treatment Programs
TypeProfessional Services
Description

NESA Clinics (partner clinics) offer NESA neuromodulation sessions to patients, typically structured as session packages or blocks rather than single-session bookings. Each clinic sets its own pricing. Treatment programs include a comprehensive initial assessment, a personal patient kit, a series of sessions with a personalized plan, measurement tools (validated questionnaires, ECG/HRV in many cases), and regular reassessments. Revenue flows to the clinic, not directly to Nesa World, but this drives clinic adoption of the device.

nesa.world
3Training and Education – NESA Academic
TypeProfessional Services
Description

Nesa World provides online and in-person training via the NESA Academic campus, integrated into device tier packages (Esencial includes basic online training; Profesional adds advanced online or in-person training; Premium includes on-site accompaniment and mentoring). Training is a value driver for adoption and may represent an additional service revenue stream.

nesa.world
4Scientific Dossier and Research Support Services
TypeManaged Services
Description

Nesa World produces and distributes a biannual scientific dossier compiling completed research, ongoing studies, and pending projects (available to professionals and collaborators). They also provide technical, academic, and operational support to hospitals and universities for integrating non-invasive neuromodulation into their own research lines, including doctoral thesis support. This reinforces brand credibility and drives institutional adoption.

nesa.world
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details3 tiers
1Esencial tier: Core device package with basic accessories and online training
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Includes NESA XSIGNAL® device complete with cables, electrosupports and basic accessories; initial online training; access to the NESA academic campus; standard technical support. Ideal for clinics that already integrate technology and have a team that learns quickly.

nesa.world
2Profesional tier (most popular): Expanded kit, advanced training, and enhanced support
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Includes expanded kit of clinical materials and patient communication resources; advanced online or in-person training; clinical reasoning guide by specialty; patient communication resources; reinforced support for the first 90 days. Ideal for clinics wanting to standardize and communicate effectively from day 1.

nesa.world
3Premium tier: On-site accompaniment, advanced mentoring, and priority continuous support
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Includes on-site accompaniment at the center; advanced training with clinical cases and mentoring; high-impact communication package; continuous priority support; access to the NESA center network. Ideal for clinics seeking a turnkey implementation with maximum speed of deployment.

nesa.world
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1NESA XSIGNAL®
Description

Class IIa medical device for non-invasive neuromodulation of the autonomic nervous system using microcurrents applied through electrodes on wrists and ankles.

nesa.world
+2 more records
Core offering1 text field

Nesa World (legally NGS Health and Mind S.L.) develops and commercializes NESA XSIGNAL®, a Class IIa non-invasive neuromodulation medical device that delivers subsensory microcurrents through 24 surface electrodes placed at distal low-impedance points to modulate the autonomic nervous system. The device is offered to healthcare professionals and clinics in three tiers (Esencial, Profesional, Premium), complemented by per-patient Personal Patient Kit consumables and the NESA Academic training campus.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • Sleep quality improvement: up to 49.0% improvement; REM sleep strength +20.1%; total hours of sleep +23.7%; nocturnal awakenings -64.4%; sleep interruptions -69.5%; daytime sleepiness -57.9%; family sleep quality +24.0%
+7 more records
Product overview1 text field

Nesa World offers non-invasive neuromodulation technology through its flagship product NESA XSIGNAL®, a Class IIa medical device that applies microcurrents to modulate the autonomic nervous system. The company provides this through three service tiers (Esencial, Profesional, Premium) which differ in level of support, training, and materials rather than the device itself. NESA XSIGNAL® is available in clinics across 47+ countries and serves multiple clinical specialties including rehabilitation, intimate health, sports medicine, mental health, neurology, dentistry, internal medicine, and aesthetic medicine.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1Universidad de Las Palmas de Gran Canaria (ULPGC)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

NESA World established its Electrophysiology Laboratory at ULPGC in 2019. The lab is equipped with specialized tools for autonomic nervous system analysis, actigraphy, ECG, EGG, and biomarkers. It leads proprietary research projects and collaborates with external research groups. The lab produces a biannual scientific dossier of completed research, ongoing studies, and pending projects, distributed to professionals and collaborators. This is a flagship research partnership providing the scientific foundation for NESA technology.

nesa.world
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Formal research agreement for NESA neuromodulation studies. The university's I+D Laboratory (led by Dr. Carlos Romero) and faculty members including Dr. Monica de la Cueva and Beatriz Martinez (pelvic floor physiotherapist and teacher) participate in collaborative research on NESA applications across clinical areas.

3Universidad Rey Juan Carlos (URJC)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration including work on long COVID dysautonomia. Dr. Cesar Fernandez de las Peñas and Dr. Ana Isabel de la Llave are key collaborators. URJC participates in the Long COVID unit research with NESA neuromodulation. Dr. Raquel Medina also collaborates directly with ULPGC.

nesa.world
4Universidad de Castilla-La Mancha (UCLM)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Formal research agreement with UCLM. Dr. Raquel Medina serves as laboratory director. Rectors and deans have participated in agreement ceremonies. The collaboration supports doctoral thesis development and independent research on autonomic neuromodulation.

nesa.world
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NESA Electrophysiology Laboratory established at UAX. Collaboration includes Rector Isabel Fernandez, Health Sciences Director, faculty members Pablo Aparicio and Dr. Lopez Roman (Director of the Virtual Hospital). Supports academic research and training in NESA neuromodulation applications.

6Universidad de Alcala (UAH)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NESA Electrophysiology Laboratory at UAH. Dr. Tomas Gallego (Dean of Physiotherapy) and Dr. Daniel Pecos (Vice-Dean) participate in collaborative research and academic activities related to autonomic neuromodulation.

nesa.world
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with FC Barcelona's innovation hub studying the 'neuroefficiency' of basketball players using NESA technology. A published clinical trial (García et al., 2022, Frontiers in Physiology) demonstrated improved physiological recovery in professional basketball players. The partnership provides high-profile sports medicine credibility and athlete-specific outcomes data.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial partnership studying improved recovery in anterior cruciate ligament (ACL) reconstruction with NESA neuromodulation. Key collaborators include Dr. Jordi Puigdelli (FC Barcelona Traumatologist), Dr. Albert Estiarte (Director), Dr. Griselda Sirvent (Head of Rehabilitation), and Oscar Muncunill (Physiotherapist). Produces clinical evidence for sports rehabilitation applications.

9Servicio Canario de la Salud
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial partnership studying overactive bladder improvement with NESA technology. Conducted at Hospital Materno Infantil with Dr. Alicia Martin (Gynecologist, Head of Service), Dr. Guillermo Conde (Urologist, Head of Service), and institutional collaborators. Produces peer-reviewed urology/gynecology evidence published in Journal of Clinical Medicine.

nesa.world
10Hospital San Juan de Dios (San Sebastian)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partnership studying post-operative improvement of knee prostheses with NESA neuromodulation. Key collaborators include Jose Carlos del Castillo (Medical Director), Dr. Inmaculada Fierro (Rehabilitation Medical Director), Dr. Ramon Moreno (Traumatologist), and Yaiza Rodriguez (Physiotherapist). Provides evidence for post-surgical rehabilitation applications.

nesa.world
11Ciudad San Juan de Dios Las Palmas
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partnership studying improvement in constipation and nocturnal spasticity with NESA neuromodulation. Clinical coordinator Iraya Padron leads the collaboration, producing evidence for neurological and gastroenterological applications including pediatric neurodevelopmental disorders.

nesa.world
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Magstim
TypeBroad incumbent
Description

Magstim is an established manufacturer of transcranial magnetic stimulation (TMS) systems and neuronavigation tools used in psychiatry, neurology, and neuroscience research. While it competes in the broader non-invasive neuromodulation category, its modality (magnetic rather than microcurrent) and customer profile (psychiatry and research hospitals) differ from NESA's autonomic/via-distal-electrodes approach.

TypeEmerging player
Description

MindMaze develops digital neurotherapeutics, brain-computer interfaces, and neurorehabilitation platforms combining software and sensors for stroke recovery and cognitive assessment. Comparable as an emerging player that combines neuromodulation/neurotechnology with clinical evidence-driven positioning for rehabilitation, though its delivery modality (digital/BCI) differs from NESA's hardware-electrode approach.

TypeEmerging player
Description

Dreem (and parent Beacon Biosignals) develops neurotechnology and sleep-monitoring/EEG-based devices targeting sleep improvement and autonomic/sleep research. Comparable as an emerging neurotechnology player addressing sleep and autonomic regulation - key outcomes in NESA's published evidence - via a different modality (wearable/EEG headband).

4BTL Industries
TypeBroad incumbent
Description

BTL Industries manufactures a broad portfolio of non-invasive medical and aesthetic devices, including EMS body-shaping systems (Emsculpt), focused shockwave therapy, and high-intensity electromagnetic/electrical stimulation platforms sold to clinics globally. It is a broad incumbent in non-invasive clinic-grade electrical stimulation, but its core portfolio is aesthetic/orthopedic rather than autonomic neuromodulation.

TypeOthers
Description

Saluda Medical develops implantable closed-loop spinal cord stimulation systems for chronic pain and other neurological conditions, with FDA-cleared devices. Included as an adjacent/ecosystem peer in the neuromodulation space addressing chronic pain - one of NESA's core indications - though its invasive, surgical-implant approach contrasts with NESA's non-invasive positioning.

6Neurosoft
TypeBroad incumbent
Description

Neurosoft produces a range of neurophysiological and neurostimulation equipment (EEG, EMG, TMS, and therapeutic stimulation devices) sold to hospitals and research institutions. Comparable as a broader medical-device incumbent in the neurostimulation space, though its offering spans many modalities beyond NESA's autonomic microcurrent focus.

TypeDirect peer
Description

Cefaly manufactures a non-invasive external trigeminal nerve stimulation device (Class II medical device) primarily indicated for migraine prevention and acute treatment, marketed to neurologists and headache specialists. Like Nesa World, Cefaly sells a hardware device through clinicians with a CE-marked, app-enabled, microcurrent-based neuromodulation platform targeting an underserved therapeutic area.

TypeDirect peer
Description

electroCore markets gammaCore, a non-invasive vagus nerve stimulation (nVNS) device for migraine, cluster headache, and autonomic-related indications, sold through healthcare providers and reimbursed in select markets. It is a direct functional analog to NESA XSIGNAL® in that both deliver non-invasive autonomic neuromodulation via surface electrodes to treat overlapping conditions including headache, pain, and autonomic dysregulation.

TypeDirect peer
Description

Soterix Medical develops non-invasive transcranial direct current stimulation (tDCS) and transcranial electrical stimulation devices used in research and clinical neurology/rehabilitation settings. Comparable to Nesa World in deploying Class II-equivalent, electrode-based electrical neuromodulation hardware to clinicians and researchers for therapeutic and rehabilitation applications.

TypeOthers
Description

Boston Scientific's Neuromodulation division (which absorbed Cosman Medical's RF pain technology) is a global incumbent in spinal cord stimulation, radiofrequency ablation, and deep brain stimulation for chronic pain and movement disorders. Included as an adjacent large-cap incumbent whose pain-neuromodulation portfolio frames the market context for NESA's non-invasive chronic pain offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment10 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nesa World

Neuromodulation Medical Devicesnesa.world

Nesa World is a privately held Spanish medical technology company that develops and distributes NESA XSIGNAL®, a Class IIa non-invasive autonomic neuromodulation device sold to independent clinics, hospitals, and research institutions across 47+ countries for chronic pain, sleep, fatigue, and urological indications.

What Nesa World does

Nesa World (legally NGS Health and Mind S.L.) is a privately held Spanish medical technology company headquartered in San Sebastián (Donostia), Spain, that develops and distributes NESA XSIGNAL®, a Class IIa medical device for non-invasive autonomic neuromodulation. The device applies subsensory microcurrents (below 1 mA) through 24 surface electrodes placed on the wrists and ankles, delivering up to 19,000 bioelectrical impulses per minute at frequencies between 1 and 14 Hz. Its mechanism acts through three complementary pathways: classical afferent neurotransmission via peripheral nerves to the brainstem, bioelectrical communication through the piezoelectric fascial network, and neuroimmune modulation via the vagal pathway, with the goal of restoring sympathetic-parasympathetic balance in patients with chronic pain, sleep disturbances, fatigue, overactive bladder, stress, and related conditions.

The company sells the device through three tiers (Esencial, Profesional, Premium) to independent clinics, hospitals, and research institutions across more than 47 countries, with over 1,000 clinics and 50+ hospitals in its installed base and 4M+ cumulative patient sessions performed. Revenue is generated primarily through one-time hardware sales (with flexible acquisition options including outright purchase, payment plans, and rental for select home use), supplemented by recurring consumables (personal patient kits assigned per patient for hygiene and traceability), training and education services via the NESA Academic campus, and scientific dossier and research support services. Distribution combines a direct authorized clinic network, regional distributors, and academic/hospital research partnerships, supported by a public clinic locator and a multi-language marketing presence targeting healthcare professionals across rehabilitation, urogynecology, sports medicine, mental health, neurology, dentistry, internal medicine, and aesthetic medicine.

Nesa World's competitive positioning rests on more than three decades of technology evolution from a 192-electrode Japanese prototype, a portfolio of 16+ peer-reviewed clinical studies in indexed journals, a dedicated Electrophysiology Laboratory at ULPGC, and 15+ institutional research collaborations. The company is privately held with no disclosed external funding rounds, and operates with a headcount of 11–50 employees.

Nesa World firmographics

Firmographics
Name
Nesa World
Legal name
NGS Health and Mind S.L
Website
https://nesa.world
Company type
Private
Operating status
Operating
Headcount range
51–100 employees
Short description
Nesa World is a privately held Spanish medical technology company that develops and distributes NESA XSIGNAL®, a Class IIa non-invasive autonomic neuromodulation device sold to independent clinics, hospitals, and research institutions across 47+ countries for chronic pain, sleep, fatigue, and urological indications.
Ownership category
akta.pro rank

Where Nesa World is headquartered

Location

Headquarters

HQ city
Donostia-san Sebastián
HQ country
Spain
HQ region
Europe

Offices2 records

Markets served

Nesa World business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Medical Device Sales – NESA XSIGNAL®: Nesa World sells NESA XSIGNAL® medical devices (Class IIa) to healthcare professionals and clinics through a tiered offering model (Esencial, Profesional, Premium). The device is offered with flexible acquisition options including outright purchase, payment plans, and device rental for home treatment in select cases. Many clinics amortize the investment within the first months by bundling the device into session packages. Each tier includes varying levels of onboarding, training, clinical materials, and support. The revenue is predominantly a one-time capital expense for the device, supplemented by ongoing consumables (personal patient kits) and potentially premium support contracts.
  2. Session Packages and Treatment Programs: NESA Clinics (partner clinics) offer NESA neuromodulation sessions to patients, typically structured as session packages or blocks rather than single-session bookings. Each clinic sets its own pricing. Treatment programs include a comprehensive initial assessment, a personal patient kit, a series of sessions with a personalized plan, measurement tools (validated questionnaires, ECG/HRV in many cases), and regular reassessments. Revenue flows to the clinic, not directly to Nesa World, but this drives clinic adoption of the device.
  3. Training and Education – NESA Academic: Nesa World provides online and in-person training via the NESA Academic campus, integrated into device tier packages (Esencial includes basic online training; Profesional adds advanced online or in-person training; Premium includes on-site accompaniment and mentoring). Training is a value driver for adoption and may represent an additional service revenue stream.
  4. Scientific Dossier and Research Support Services: Nesa World produces and distributes a biannual scientific dossier compiling completed research, ongoing studies, and pending projects (available to professionals and collaborators). They also provide technical, academic, and operational support to hospitals and universities for integrating non-invasive neuromodulation into their own research lines, including doctoral thesis support. This reinforces brand credibility and drives institutional adoption.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractEsencial tier: Core device package with basic accessories and online training
One time/ perpetual licenseMulti-year contractProfesional tier (most popular): Expanded kit, advanced training, and enhanced support
One time/ perpetual licenseMulti-year contractPremium tier: On-site accompaniment, advanced mentoring, and priority continuous support

Go-to-market motion3 records

Distribution channels5 records

Marketing channels10 records

Nesa World product offering

Product offering

Core offering

Nesa World (legally NGS Health and Mind S.L.) develops and commercializes NESA XSIGNAL®, a Class IIa non-invasive neuromodulation medical device that delivers subsensory microcurrents through 24 surface electrodes placed at distal low-impedance points to modulate the autonomic nervous system. The device is offered to healthcare professionals and clinics in three tiers (Esencial, Profesional, Premium), complemented by per-patient Personal Patient Kit consumables and the NESA Academic training campus.

Product overview

Nesa World offers non-invasive neuromodulation technology through its flagship product NESA XSIGNAL®, a Class IIa medical device that applies microcurrents to modulate the autonomic nervous system. The company provides this through three service tiers (Esencial, Profesional, Premium) which differ in level of support, training, and materials rather than the device itself. NESA XSIGNAL® is available in clinics across 47+ countries and serves multiple clinical specialties including rehabilitation, intimate health, sports medicine, mental health, neurology, dentistry, internal medicine, and aesthetic medicine.

Differentiator

Problem solved

Functional benefit

Brands

  • NESA XSIGNAL®: Class IIa medical device for non-invasive neuromodulation of the autonomic nervous system using microcurrents applied through electrodes on wrists and ankles.
  • Nesa Clinics
  • Nesa Academic

Quantifiable outcome

  • Sleep quality improvement: up to 49.0% improvement; REM sleep strength +20.1%; total hours of sleep +23.7%; nocturnal awakenings -64.4%; sleep interruptions -69.5%; daytime sleepiness -57.9%; family sleep quality +24.0%
  • +7 more outcomes

Companies that use Nesa World

Customer profile

Named customers10 records

Segments10 records

Ideal customer profiles2 records

Nesa World technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Nesa World partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core.

  • Universidad de Las Palmas de Gran Canaria (ULPGC)coreStrategic or Co-development Partner · 1 January 2019NESA World established its Electrophysiology Laboratory at ULPGC in 2019. The lab is equipped with specialized tools for autonomic nervous system analysis, actigraphy, ECG, EGG, and biomarkers. It leads proprietary research projects and collaborates with external research groups. The lab produces a biannual scientific dossier of completed research, ongoing studies, and pending projects, distributed to professionals and collaborators. This is a flagship research partnership providing the scientific foundation for NESA technology.
  • Universidad Europea de Madrid (UE)coreStrategic or Co-development PartnerFormal research agreement for NESA neuromodulation studies. The university's I+D Laboratory (led by Dr. Carlos Romero) and faculty members including Dr. Monica de la Cueva and Beatriz Martinez (pelvic floor physiotherapist and teacher) participate in collaborative research on NESA applications across clinical areas.
  • Universidad Rey Juan Carlos (URJC)coreStrategic or Co-development PartnerResearch collaboration including work on long COVID dysautonomia. Dr. Cesar Fernandez de las Peñas and Dr. Ana Isabel de la Llave are key collaborators. URJC participates in the Long COVID unit research with NESA neuromodulation. Dr. Raquel Medina also collaborates directly with ULPGC.
  • Universidad de Castilla-La Mancha (UCLM)coreStrategic or Co-development PartnerFormal research agreement with UCLM. Dr. Raquel Medina serves as laboratory director. Rectors and deans have participated in agreement ceremonies. The collaboration supports doctoral thesis development and independent research on autonomic neuromodulation.
  • Universidad Alfonso X El Sabio (UAX)coreStrategic or Co-development PartnerNESA Electrophysiology Laboratory established at UAX. Collaboration includes Rector Isabel Fernandez, Health Sciences Director, faculty members Pablo Aparicio and Dr. Lopez Roman (Director of the Virtual Hospital). Supports academic research and training in NESA neuromodulation applications.
  • Universidad de Alcala (UAH)coreStrategic or Co-development PartnerNESA Electrophysiology Laboratory at UAH. Dr. Tomas Gallego (Dean of Physiotherapy) and Dr. Daniel Pecos (Vice-Dean) participate in collaborative research and academic activities related to autonomic neuromodulation.
  • FC Barcelona Innovation Hub (Barça Innovation Hub)coreStrategic or Co-development PartnerResearch collaboration with FC Barcelona's innovation hub studying the 'neuroefficiency' of basketball players using NESA technology. A published clinical trial (García et al., 2022, Frontiers in Physiology) demonstrated improved physiological recovery in professional basketball players. The partnership provides high-profile sports medicine credibility and athlete-specific outcomes data.
  • Clinica Sant JosepcoreStrategic or Co-development PartnerClinical trial partnership studying improved recovery in anterior cruciate ligament (ACL) reconstruction with NESA neuromodulation. Key collaborators include Dr. Jordi Puigdelli (FC Barcelona Traumatologist), Dr. Albert Estiarte (Director), Dr. Griselda Sirvent (Head of Rehabilitation), and Oscar Muncunill (Physiotherapist). Produces clinical evidence for sports rehabilitation applications.
  • Servicio Canario de la SaludcoreStrategic or Co-development PartnerClinical trial partnership studying overactive bladder improvement with NESA technology. Conducted at Hospital Materno Infantil with Dr. Alicia Martin (Gynecologist, Head of Service), Dr. Guillermo Conde (Urologist, Head of Service), and institutional collaborators. Produces peer-reviewed urology/gynecology evidence published in Journal of Clinical Medicine.
  • Hospital San Juan de Dios (San Sebastian)coreStrategic or Co-development PartnerResearch partnership studying post-operative improvement of knee prostheses with NESA neuromodulation. Key collaborators include Jose Carlos del Castillo (Medical Director), Dr. Inmaculada Fierro (Rehabilitation Medical Director), Dr. Ramon Moreno (Traumatologist), and Yaiza Rodriguez (Physiotherapist). Provides evidence for post-surgical rehabilitation applications.
  • Ciudad San Juan de Dios Las PalmascoreStrategic or Co-development PartnerResearch partnership studying improvement in constipation and nocturnal spasticity with NESA neuromodulation. Clinical coordinator Iraya Padron leads the collaboration, producing evidence for neurological and gastroenterological applications including pediatric neurodevelopmental disorders.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Nesa World competitors and assessment

Company assessment

Broad incumbents

  • Magstim: Magstim is an established manufacturer of transcranial magnetic stimulation (TMS) systems and neuronavigation tools used in psychiatry, neurology, and neuroscience research. While it competes in the broader non-invasive neuromodulation category, its modality (magnetic rather than microcurrent) and customer profile (psychiatry and research hospitals) differ from NESA's autonomic/via-distal-electrodes approach.
  • BTL Industries: BTL Industries manufactures a broad portfolio of non-invasive medical and aesthetic devices, including EMS body-shaping systems (Emsculpt), focused shockwave therapy, and high-intensity electromagnetic/electrical stimulation platforms sold to clinics globally. It is a broad incumbent in non-invasive clinic-grade electrical stimulation, but its core portfolio is aesthetic/orthopedic rather than autonomic neuromodulation.
  • Neurosoft: Neurosoft produces a range of neurophysiological and neurostimulation equipment (EEG, EMG, TMS, and therapeutic stimulation devices) sold to hospitals and research institutions. Comparable as a broader medical-device incumbent in the neurostimulation space, though its offering spans many modalities beyond NESA's autonomic microcurrent focus.

Emerging players

  • MindMaze: MindMaze develops digital neurotherapeutics, brain-computer interfaces, and neurorehabilitation platforms combining software and sensors for stroke recovery and cognitive assessment. Comparable as an emerging player that combines neuromodulation/neurotechnology with clinical evidence-driven positioning for rehabilitation, though its delivery modality (digital/BCI) differs from NESA's hardware-electrode approach.
  • Dreem (Beacon Biosignals): Dreem (and parent Beacon Biosignals) develops neurotechnology and sleep-monitoring/EEG-based devices targeting sleep improvement and autonomic/sleep research. Comparable as an emerging neurotechnology player addressing sleep and autonomic regulation - key outcomes in NESA's published evidence - via a different modality (wearable/EEG headband).

Others

  • Saluda Medical: Saluda Medical develops implantable closed-loop spinal cord stimulation systems for chronic pain and other neurological conditions, with FDA-cleared devices. Included as an adjacent/ecosystem peer in the neuromodulation space addressing chronic pain - one of NESA's core indications - though its invasive, surgical-implant approach contrasts with NESA's non-invasive positioning.
  • Cosman Medical / Boston Scientific Neuromodulation: Boston Scientific's Neuromodulation division (which absorbed Cosman Medical's RF pain technology) is a global incumbent in spinal cord stimulation, radiofrequency ablation, and deep brain stimulation for chronic pain and movement disorders. Included as an adjacent large-cap incumbent whose pain-neuromodulation portfolio frames the market context for NESA's non-invasive chronic pain offering.

Direct peers

  • Cefaly: Cefaly manufactures a non-invasive external trigeminal nerve stimulation device (Class II medical device) primarily indicated for migraine prevention and acute treatment, marketed to neurologists and headache specialists. Like Nesa World, Cefaly sells a hardware device through clinicians with a CE-marked, app-enabled, microcurrent-based neuromodulation platform targeting an underserved therapeutic area.
  • electroCore (gammaCore): electroCore markets gammaCore, a non-invasive vagus nerve stimulation (nVNS) device for migraine, cluster headache, and autonomic-related indications, sold through healthcare providers and reimbursed in select markets. It is a direct functional analog to NESA XSIGNAL® in that both deliver non-invasive autonomic neuromodulation via surface electrodes to treat overlapping conditions including headache, pain, and autonomic dysregulation.
  • Soterix Medical: Soterix Medical develops non-invasive transcranial direct current stimulation (tDCS) and transcranial electrical stimulation devices used in research and clinical neurology/rehabilitation settings. Comparable to Nesa World in deploying Class II-equivalent, electrode-based electrical neuromodulation hardware to clinicians and researchers for therapeutic and rehabilitation applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Nesa World social profiles

Digital presence

Nesa World compliance and trust

Trust signal

Compliance4 records

Nesa World financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nesa World leadership team

Management profile

Number of profiles

Nesa World funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nesa World M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nesa World

What does Nesa World do?

Nesa World (legally NGS Health and Mind S.L.) develops and commercializes NESA XSIGNAL®, a Class IIa non-invasive neuromodulation medical device that delivers subsensory microcurrents through 24 surface electrodes placed at distal low-impedance points to modulate the autonomic nervous system. The device is offered to healthcare professionals and clinics in three tiers (Esencial, Profesional, Premium), complemented by per-patient Personal Patient Kit consumables and the NESA Academic training campus.

Is Nesa World a public or private company?

Nesa World is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Nesa World founded?

Nesa World was founded in -1. It employs 51 to 100 people.

Where is Nesa World based?

Nesa World is headquartered in Donostia-san Sebastián, Spain, in the Europe region.

How does Nesa World make money?

Four revenue lines are on record. Medical Device Sales – NESA XSIGNAL® is the primary driver. The others are session Packages and Treatment Programs, training and Education – NESA Academic and scientific Dossier and Research Support Services.

Who are Nesa World's main competitors?

Broad incumbents on record are Magstim, BTL Industries and Neurosoft. Emerging players are MindMaze and Dreem (Beacon Biosignals). Others are Saluda Medical and Cosman Medical / Boston Scientific Neuromodulation. Direct peers are Cefaly, electroCore (gammaCore) and Soterix Medical.

Does Nesa World have an API?

No public API is recorded for Nesa World.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals